The Story of Deep Capture
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
@Ttalibrary @Ttalibrary BULL! Ba History of the Boom and Bust, 1982–2004
@ttalibrary @ttalibrary BULL! Ba history of the boom and bust, 1982–2004 maggie mahar @ttalibrary To Raymond, who believes that everything is possible @ttalibrary — Contents — Acknowledgments vii Prologue Henry Blodget xiii Introduction Chapter 1—The Market’s Cycles 3 Chapter 2—The People’s Market 17 Beginnings (1961–89) Chapter 3—The Stage Is Set 35 (1961–81) Chapter 4—The Curtain Rises 48 (1982–87) Chapter 5—Black Monday (1987–89) 61 @ttalibrary iv Contents The Cast Assembles (1990–95) Chapter 6—The Gurus 81 Chapter 7—The Individual Investor 102 Chapter 8—Behind the Scenes, 123 in Washington The Media, Momentum, and Mutual Funds (1995–96) Chapter 9—The Media: CNBC Lays 153 Down the Rhythm Chapter 10—The Information Bomb 175 Chapter 11—AOL: A Case Study 193 Chapter 12—Mutual Funds: 203 Momentum versus Value Chapter 13—The Mutual Fund 217 Manager: Career Risk versus Investment Risk The New Economy (1996–98) Chapter 14—Abby Cohen Goes to 239 Washington; Alan Greenspan Gives a Speech Chapter 15—The Miracle of 254 Productivity The Final Run-Up (1998–2000) Chapter 16—“Fully Deluded 269 Earnings” @ttalibrary Contents v Chapter 17—Following the Herd: 288 Dow 10,000 Chapter 18—The Last Bear Is Gored 304 Chapter 19—Insiders Sell; 317 the Water Rises A Final Accounting Chapter 20—Winners, Losers, and Scapegoats 333 (2000–03) Chapter 21—Looking Ahead: What 353 Financial Cycles Mean for the 21st-Century Investor Epilogue (2004–05) 387 Notes 397 Appendix 473 Index 481 about the author credits cover copyright about the publisher @ttalibrary @ttalibrary — Acknowledgments — More than a hundred people contributed to this book, sharing their expe- riences, their insights, and their knowledge. -
The Story of Deep Capture
The Columbia School of Journalism is our nation’s finest. They grant the Pulitzer Prize, and their journal, The Columbia Journalism Review, is the profession’s gold standard. CJR reporters are high priests of a decaying temple, tending a flame in a land going dark. In 2006 a CJR editor (a seasoned journalist formerly with Time magazine in Asia, The Wall Street Journal Europe, and The Far Eastern Economic Review) called me to discuss suspicions he was forming about the US financial media. I gave him leads but warned, “Chasing this will take you down a rabbit hole with no bottom.” For months he pursued his story against pressure and threats he once described as, “something out of a Hollywood B movie, but unlike the movies, the evil corporations fighting the journalist are not thugs burying toxic waste, they are Wall Street and the financial media itself.” His exposé reveals a circle of corruption enclosing venerable Wall Street banks, shady offshore financiers, and suspiciously compliant reporters at The Wall Street Journal, Fortune, CNBC, and The New York Times. If you ever wonder how reporters react when a journalist investigates them (answer: like white-collar crooks they dodge interviews, lie, and hide behind lawyers), or if financial corruption interests you, then this is for you. It makes Grisham read like a book of bedtime stories, and exposes a scandal that may make Enron look like an afternoon tea. By Patrick M. Byrne, Deep Capture Reporter The Story of Deep Capture By Mark Mitchell, with reporting by the Deep Capture Team Introduction - by Mark Mitchell I began working on a version of this story in January 2006, while serving as an editor for the Columbia Journalism Review, a publication tasked with upholding the standards of the American media. -
Comment Letter
During June and July of 2009 Deep Capture serialized a 48,000 word story about a network of market miscreants that includes disreputable financial analysts, prominent journalists, some of America’s best-known hedge fund managers, associates of the Mafia, and Michael Milken, the famous criminal from the 1980s. The story focuses on the travails of Dendreon, a company with a promising treatment for prostate cancer, but it describes market machinations that have affected hundreds of other companies, and it contains a larger message about the “deep capture” of our nation’s media and regulatory bodies. Now we publish the full, 15-chapter story as a single document…. * * * * * * * * This story, like too many others, begins with Jim Cramer, the CNBC personality, making “a mistake.” On September 26, 2005, Cramer announced to his television audience the sad news (punctuated by funny sound effects – a clown horn, a crashing airplane) that Provenge, an experimental treatment for prostate cancer, had flopped. Thousands of end-stage patients had been pinning their hopes on Provenge, but according to Cramer the treatment had just been rejected by the Food & Drug Administration. It would never go to market. This seemed odd, because Dendreon (NASDAQ: DNDN), the company developing Provenge, had not yet submitted an application for FDA approval. As everybody in the biotech investment community knew, in fact, Dendreon had only recently completed Phase 3 clinical trials and probably would not face scrutiny from an FDA advisory panel for at least another year. As for the likelihood that the advisory panel would eventually vote in favor of Provenge, the odds looked good.